A post-marketing review by the FDA detected an increased risk of the autoimmune condition in patients inoculated with GSK’s ...
Guillain-Barré syndrome (GBS) is an acute inflammatory ... determined in serum samples pretreatment and again 2 weeks after treatment. Some patients also had IgG levels measured at 4 weeks ...
The change was prompted by postmarketing observational studies that suggest an increased risk of GBS within 42 days of ...
On the other hand, if the FDA rejects Annexon's filing, Annexon may have to go back and revise its RWE study or even open a ...
Any debate about whether to enhance the domestic supply of blood plasma by allowing payments to donors should consider these ...
In China, acupuncture therapy is a common treatment for neurogenic bladder due to SCI, but its effects and safety remain uncertain. A protocol is described ... multiple sclerosis, Guillain-Barre ...
Findings from a postmarketing observational study showed an increased risk of GBS during the 42 days following vaccination.
Medpage Today on MSN3d
FDA Adds Guillain-Barre Syndrome Warning to Two RSV VaccinesThe CDC recommends a single dose of any FDA-approved RSV vaccine for all adults ages 75 years and older, as well as for 60- ...
The FDA is adding a warning about Guillain-Barré syndrome to the respiratory syncytial virus vaccines manufactured by GSK and ...
Regulators say, however, the benefits of vaccination with Abrysvo and Arexvy in preventing respiratory syncytial virus ...
Background: Little is known about the long term prognosis for patients the severe acute motor axonal neuropathy (AMAN) form of Guillain–Barré syndrome (GBS), unlike those with acute inflammatory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback